外周血细胞参数对CD19-CART治疗难治/复发急性B淋巴细胞白血病疗效的预测作用

摘要/Abstract

摘要： 目的研究外周血细胞参数在CD19-嵌合型抗原受体T细胞（CD19-CAR-T）治疗难治/复发急性B淋巴细胞白血病中的作用。方法回顾性分析2017年5月~2020年5月在北京陆道培医院接受CD19-CAR-T治疗难治/复发急性B淋巴细胞白血病患者的临床资料,比较治疗后46例CAR-T细胞治疗后微小残留病（MRD）阴性患者（MRD阴性组）和38例微小残留病阳性患者（MRD阳性组）治疗过程中的外周血细胞参数。结果 MRD阴性组在CD19-CAR-T细胞回输时白细胞、血红蛋白、血小板和中性粒细胞数值,明显高于MRD阳性组患者,差异具有统计学意义（P<0.05）。MRD阴性组在回输第7天、第14天、第21天的血小板数值明显高于MRD阳性组,差异具有统计学意义（P<0.05）。结论 CD19-CAR-T细胞回输时外周血细胞数值高,第7天、第14天、第21天血小板数值高,可能预示CD19-CAR-T细胞治疗有效;与化疗相比较,CD19-CAR-T细胞治疗后的造血恢复速度更快。

关键词: 急性淋巴细胞白血病, 嵌合型抗原受体, 血小板, 难治, 复发

Abstract: Objective To study the effect of peripheral blood cell paremeters in the patients with refractory/relapsed acute B-lymphoblastic leukemia treated with CD19 chimeric antigen receptor T cells (CD19-CAR-T). Methods We retrospectively analyzed the clinical data of patients with refractory/relapsed acute B-lymphoblastic leukemia treated with CD19-CAR-T cells in Beijing Ludaopei hospital from May 2017 to May 2020 . The peripheral blood cell parameters were compared between 46 patients with minimal residual disease (MRD) negative (MRD negative group) and 38 patients with minimal residual disease positive (MRD positive group) after CAR-T cells therapy. Results The mean values of leukocytes, hemoglobin, platelets and neutrophils(LHPN0) in the MRD negative group were significantly higher than those in the MRD positive group on the day of CAR-T cells transfusion, and the differencewas statistically significant (P<0.05). The mean platelet values on the 7th, 14th and 21st day (PLT7, PLT14, PLT21)after CD19-CAR-T cells transfusion were significantly higher in the MRD negative group than those in the MRD positive group, respectively, and the differencewas statistically significant (P<0.05). Conclusion The higher value of LHPN0, PLT7, PLT14, PLT21 may indicate that CD19-CAR-T cell treatment may be effective. The hematopoietic recovery is faster after CD19-CAR-T treatment than after chemotherapy.

Key words: acute lymphoblastic leukemia, chimeric antigen receptor, platelet, relapsed, refractory

中图分类号:

R733.7

张战强, 张改玲, 苏云超, 何九江, 张敏, 杨君芳, 张弦. 外周血细胞参数对CD19-CART治疗难治/复发急性B淋巴细胞白血病疗效的预测作用[J]. 中华养生保健, 2022, 40(14): 1-4.

ZHANG Zhan-Qiang, ZHANG Gai-Ling, SU Yun-Chao, HE Jiu-Jiang, ZHANG Min, YANG Jun-Fang, ZHANG Xian. The Effect of Peripheral Blood Cell Paremeters in the Patients with Refractory/Relapsed Acute B-Lymphoblastic Leukemia Treated with CD19 -CAR- T Cells[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(14): 1-4.

参考文献

[1] Hunger SP, Mullighan CG.Acute Lymphoblastic Leukemia in Children[J].N Engl J Med,2015,373:1541-1552.
[2] Benjamin R, Graham C, Yallop D, et al.Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies[J].Lancet,2020,396:1885-1894.
[3] Maus MV.CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia[J].Lancet,2021,398:466-467.
[4] Maude SL, Laetsch TW, Buechner J, et al.Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia[J].N Engl J Med,2018.378:439-448.
[5] Malard F, Mohty M.Acute lymphoblastic leukaemia[J].Lancet,2020,395:1146-1162.
[6] Lee DW, Gardner R, Porter DL, et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124:188-195.
[7] Shimabukuro-Vornhagen A, Böll B, Schellongowski P, et al.Critical care management of chimeric antigen receptor T-cell therapy recipients[J].CA Cancer J Clin,2022,72:78-93.
[8] Neelapu SS, Tummala S, Kebriaei P, et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15:47-62.
[9] Couzin-Frankel J.Breakthrough of the year 2013. Cancer immunotherapy[J].Science,2013,342:1432-1433.
[10] McNutt M. Cancer immunotherapy[J].Science,2013,342:1417.
[11] Subburaj D, Vaidyanathan L, Uppuluri R, et al.Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India[J].Indian J Hematol Blood Transfus,2018,34:43-47.
[12] Wang ZD, Wang YW, Xu LP, et al.Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia[J].Curr Med Sci,2021,41:443-453.
[13] Park JH, Rivière I, Gonen M, et al.Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J].N Engl J Med,2018,378:449-459.
[14] Zeidler L, Zimmermann M, Möricke A, et al.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome[J].Haematologica,2012,97:402-409.
[15] Wang Y, Zhang G, Ye L, et al.Clinical value of the quantitation of average daily platelet increase during the recovery period in childhood acute lymphoblastic leukaemia[J].Platelets,2019,30:923-926.
[16] Dai Q, Shi R, Zhang G, et al.Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia[J].Medicine (Baltimore),2021,100:e25548.
[17] Faude S, Wei J, Muralidharan K, et al.Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse[J].Blood Adv,2021,5:2128-2136.